Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in southwest Ethiopia by Zawdie, Belay et al.
              
                   Non-Alcoholic Fatty Liver…                                                                 Belay  Z. et al.                      
 
 





Non-Alcoholic Fatty Liver Disease and Associated Factors among 
Type 2 Diabetic Patients in Southwest Ethiopia 
 
Belay Zawdie1*, Samuel Tadesse1, Amare Desalegn Wolide1, Tilahun 





OPEN ACCESS  
 
Citation: Belay Zawdie, Samuel Tadesse, 
Amare Desalegn Wolide, Tilahun 
Alemayehu  Nigatu, Eshetu Mulisa 
Bobasa. Non-Alcoholic Fatty Liver 
Disease and Associated Factors among 
Type 2 Diabetic Patients in Southwest 
Ethiopia. Ethiop J Health 
Sci.2017;28(1):19. 
doi:http://dx.doi.org/10.4314/ejhs.v28i1.4  
Received: July 11, 2017 
Accepted: July 14, 2017 
Published: January 1, 2018  
Copyright: © 2018 Belay Zawdie, et al . 
This is an open access article distributed 
under the terms of the Creative Commons 
Attribution License, which permits 
unrestricted use, distribution, and 
reproduction in any medium, provided the 
original author and source are credited. 
Funding: The research is funded by 
College of Public Health and Medical 
Sciences,  Jimma University. 
Competing Interests: The authors 
declare that this manuscript was approved 
by all authors in its form and that no 
competing interest exists. 
Affiliation and Correspondence: 
										1School of Biomedical Sciences, 
Faculty of Medical Sciences, Jimma 
University 
       2School of Pharmacy, Faculty of 
Health Sciences, Jimma University 















ABSTRACT   
 
      BACKGROUND: Non-alcoholic Fatty Liver Disease (NAFLD) 
among type 2 diabetic patients is completely ignored in developing 
regions like Africa paving the way for public health and economic 
burden in the region. Therefore, the main objective of this research 
was to evaluate non-alcoholic fatty liver disease and associated 
factors among type 2 diabetic patients in Southwestern Ethiopia 
attending Diabetic Clinic of Jimma University Specialized Hospital 
(JUSH).  
METHODS: Facility based cross-sectional study design was used. 
Anthropometry, fatty liver (using utrasonography), liver enzymes, 
and lipid profiles were measured among type 2 diabetic patients 
who fulfilled the inclusion criteria. Socio-demographic and clinical 
characteristics were assessed using standard questionnaires. 
RESULTS: Ninety-six (96) type 2 diabetic patients were enrolled 
and non-alcoholic fatty liver disease prevalence was 73%. Of non-
alcoholic fatty Liver disease documented patients, 35.4%, 31.3% 
and 6.3%  exhibited mild, moderate and severe fatty liver diseases, 
respectively. Alanine aminotransferase (p ≤0.001), Triacyglycerol 
(p ≤0.001), total bilirubin (p ≤0.05), direct bilirubin (p ≤0.05) and 
diabetic duration (p ≤0.01) were significantly associated with non-
alcoholic fatty liver disease among type 2 diabetic patients. The 
Aspartate aminotransferase/ Alanine aminotransferase ratio 
among non alcoholic fatty liver disease patients was greater than 
one. 
CONCLUSIONS: The magnitude of non-alcoholic fatty liver 
disease is high among study groups and it needs urgent action by 
healthcare systems. Therefore, targeted treatment approach 
inclusive of non-alcoholic fatty liver disease should be designed. 
KEYWORDS: Africa, Ethiopia, Nonalcoholic Fatty Liver Disease, 
Type 2 DM, Liver Enzymes, Lipid Profile 
 
 INTRODUCTION  
 
Diabetes mellitus (DM) is one of the major public health and 
economic burdens among chronic non-communicable diseases 
worldwide (1). The cost incurred by developed nations like US in the  
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management of DM is passing 100 billion dollars 
annually (2). It is further complicated when it is 
associated with Non-Alcoholic Fatty Liver 
Disease (NAFLD). NAFLD is “insulin resistance 
and hepatic fat accumulation in the absence of 
other identifiable causes of fat accumulation” (3, 
4). The exact identification of NAFLD co-existing 
with DM is not yet successful making the control 
programs complex (5). Althouh it has remained 
unnoticed for many years, NAFLD is the first 
leading cause of liver diseases like cirrhosis (6,7).  
Patients developing cirrhosis from NAFLD are at 
approximately 75% risk of acquiring liver cancer 
(8). The great challenge is that most of the patients 
do not manifest any overt signs and symptoms (8, 
9), and severe NAFLD can progress to liver 
failure (10).   
The worldwide prevalence of NAFLD is 20% 
in the general population and 70% amongst people 
with type 2 diabetes (11). More than a quarter of 
adults in developed nations are losing either their 
lives or jobs due to this disease (12). Even though 
there are International Diabetes Federation (IDF) 
reports regarding the projected prevalence of type 
2 DM to reach 1 million in Ethiopia, the number 
of patients developing fatty liver disease already 
acquiring DM is given less attention by health 
professionals (13).  
In clinical settings, NAFLD is diagnosed 
through checking fatty liver along with the 
establishment of the nonalcoholic nature of the 
disease process. The best method for checking 
NAFLD is liver biopsy. However, ethical 
considerations, the high cost, its invasive nature, 
discomfort and risks associated with the process 
make it difficult to assess NAFLD in all 
individuals.	 These limitations of a liver biopsy 
make laboratory tests and imaging modalities 
indispensable methods to diagnose NAFLD in 
resource limited countries (3). Serum ALT and 
GGT are widely employed to diagnose presumed 
NAFLD on a population-wide basis. However, the 
specificity, sensitivity and predictive value of this 
method is under big question as evidence showed 
that serum ALT levels may be completely normal 
in patients with advanced grade of steatohepatitis 
or even cirrhosis. It is also studied that an 
elevation of ALT does not indicate the extent of 
hepatic damage (6). Ultrasonography, computed 
tomography (CT) or magnetic resonance imaging 
(MRI) has an adequate threshold for detection of 
fatty infiltration of the liver. The major limitations 
of these modalities include: 1) inability to 
differentiate steatosis from steatohepatitis and 2) 
insensitivity in detecting steatosis of less than 25 
to 30%. Of these methods, ultrasonography is the 
most widely available and the cheapest one. This 
modality has a diagnostic sensitivity of 82 to 94% 
and specificity greater than 82% for a fatty liver 
(5).  
Type 2 DM and obesity were associated with 
NAFLD to affect the liver throughout the world 
(8). The findings of some researches also try to 
speculate the cardiovascular disease (CVD) risk of 
having NAFLD among type 2 diabetic patients 
with NAFLD as compared to type 2 diabetic 
patients without NAFLD. These associations 
could help clinicians to identify people with 
NAFLD who need more intensive therapy to 
decrease their risk of future CVD events (14-16). 
Many scientific data are available across the 
industrialized nations identifying the cause and 
risk factors for NAFLD among type 2 diabetic 
patients (6,17-19). However, the effect of NAFLD 
on the African population is completely ignored. 
Thus, it is widely feared that it may cause harsh 
public health and economic consequences in this 
part of the world (11). Therefore, the main 
objective of this study was to evaluate non-
alcoholic fatty liver disease and associated factors 
among type 2 diabetic patients in Southwestern 
Ethiopia attending diabetic clinic of Jimma 
University Specialized Hospital (JUSH). 
METHODS AND PARTICIPANTS 
 
Study area and period: The study was conducted 
from September 2014 to February 2015 in the 
Diabetic Clinic of Jimma University Specialized 
Hospital, Jimma. Jimma University Specialized 
Hospital (JUSH) is the Center of Medical 
Excellence in Southwestern Ethiopia and probably 
the one with modern medical equipment in East 
Africa. Its establishment dates back to the first 
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quarter of the 20th century (1937 G.C.) as a 
military health service. It is located in Jimma 
Town which is about 352 km Southwest of the 
capital city, Addis Ababa, in Oromia regional 
state. One thousand four hundred and fifty (1450) 
supportive and technical staffs are hired to give 
services for approximately 15,000 inpatient and 
160,000 outpatient attendants, 11,000 emergency 
cases and 4,500 deliveries in a year. Fifteen 
million people coming to the hospital from the 
catchment areas are expected to get the services of 
the hospital (20). 
 
Study design: A facility based cross-sectional 
study design. Type 2 diabetic patients 
attending the Diabetic Clinic of JUSH were 
the study subjects. The participants who 
visited the Diabetic Clinic of Jimma 
University Specialized Hospital within the six 
months of the study period were thoroughly 
evaluated. The source for the selection was all 
type 2 diabetic patients’ on follow-up 
treatment at the Diabetic Center of JUSH. The 
selected type 2 diabetic subjects were 
considered as the study population. 
 
Sample size determination and sampling 
technique: Sample size was not determined 
initially. Rather, all type 2 diabetic patients on 
follow-up during the study period were 
randomly approached and requested for their 
consent to participate in the study. After  their 
consents were obtained, the patients were 
evaluated for eligibility to be enrolled into the 
study. Nearly 1700 type 2 diabetic patients 
gave their consent to participate. However, 
based on the inclusion criteria we set for 
analysis of NAFLD, only 96 type 2 diabetic 
patients were eligible for the study. 
 
Main procedure of the study: We excluded 
patients with known chronic liver disease, 
hepatitis B surface antigen or Anti HCV positive 
through diagnosis or those tested positive during 
the study, pregnant women, patients with history 
of alcohol, cigarette smokers and patients using 
drugs which cause fatty liver or liver toxicity 
using standard questioner and respective 
assessment of data from charts. The procedures of 
Gebreegziabher et al (21) and Manyazewa et al 
(22) with slight modifications were followed in 
the determination of Hepatitis B and C status with 
standard HBsAg test kits (Guangzhou Wondfo 
Biotech Co. Ltd, China). All the information was 
documented on a coded format prepared for this 
research. 
Ninety-six [96] type 2 diabetic patients who 
fulfilled the inclusion criteria were finally 
included in the study. Five [5] ml venous blood 
was withdrawn from each study subject by 
professional nurses at the Diabetic Clinic of 
Jimma University Specialized Hospital. The whole 
blood taken was centrifuged to separate serum 
from plasma. The specimen was handled properly 
and collected in an aseptic technique and stored on 
ice in Biochemistry laboratory until used. On the 
day of clinical chemistry measurement, a formal 
laboratory request ordered by physicians was sent 
to JUSH for each selected patients. The results of 
each study participants were filled on clinical 
chemistry result report format signed by sample 
analyzer and approver. FPG, Liver function tests 
and lipid profiles were measured and analyzed by 
using automated machine in the Jimma University 
Specialized Hospital Laboratory (VegaSys 
automated chemistry analyzer with serial number 
of 201/79 Ref 16880, from AMS Via E. Barsanti 
17/a, 00012 Guidonia – Rome, Italy). TG and 
HDL were measured according to the method 
described by Abda et al (23).  Concentrations of 
Total Protein (TP), Total Bilirubin (TB) and 
Direct Bilirubin (DB) were determined manually 
(24). 
 
Non-alcoholic fatty liver (NAFLD) checking 
under Ultrasound : The selected study subjects 
were taken under ultrasonography to evaluate the 
status of their liver. This activity was performed 
by the radiologists. The patients were given 
information about the type of food they should 
avoid (fresh fruits and vegetables, fried and oily 
food, milk, eggs, bread), instructed not to drink or 
eat at least 6 hours before the test and also not to 
take medications before the ultrasound. The echo 
of liver was compared with that of the kidney by 
observing through the ultrasound (5,18,25). 
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Anthropometric measurements: All 
anthropometric measurements such as weight 
and height were made according to the WHO 
recommendations Guideline. Then, BMI was 
calculated from weight in kg divided by 
height squared (m2) and categorized as 
underweight (<18kg /m2), normal (18-
24.9kg/m2), overweight (25-29.9kg/m2) and obese 
(>30kgm2) according to WHO criteria (26). The 
data were collected by clinical nurses selected 
from JUSH for assessing anthropometric 
measurements among selected type 2 diabetic 
patients in the Diabetic Ward. Data collectors 
were given training for three days about data 
collection procedures and research ethics. In 
addition, the process of data collection was 
supervised by investigators in rotation.  
 
Data quality control: Pre-test of the tool was 
done on the Jimma University students who were 
not included in the main study by taking 5% 
respondents of the total sample size to make 
necessary correction and completeness. 
Study variables: The liver status (being without 
NAFL, being mild NAFL, moderate NAFL, 
severe NAFL), fasting blood glucose, lipid 
profiles and liver function tests were taken as 
dependent variable while  independent  variables 
were BMI, age, sex, occupation, and duration of 
diabetes. 
 
Data analysis: The collected data was checked for 
completeness, inconsistency and outliers by 
looking at their distribution. Incomplete and 
inconsistent data were excluded from the analysis. 
Finally, the collected data were entered into SPSS 
Version 20.0. The results were put as 
mean±standard error of the mean for continuous 
variables and as number for categorical variables. 
Differences among groups of continuous variables 
were compared with normal (without NAFLD) 
type two diabetic patients using one-way ANOVA 
followed by Post Hoc Tukey test. Then, that of 
categorical variables was evaluated using chi-
square. The differences were considered 
significant at p ≤ 0.05. 
 
Ethical consideration: Initially, the Research and 
Ethical Committee of the College of Health 
Sciences, Jimma University, issued us approval 
letter. Then, formal letter was written to the 
Diabetic Center and the Ultrasound Unit of Jimma 
University Specialized Hospital. The objectives of 
the study were briefly explained to all the 
concerned bodies assigned in the hospital to get 
permission and support. Also, the aim of the study 
and its procedures were explained to the study 
participants who then gave written informed 
consent before the evaluation. The confidentiality 
of the data was strictly maintained throughout the 
study. 
 
RESULTS   
 
 
A high proportion of patients with type 2 diabetes 
mellitus were screened for this facility based 
study. However, only ninety-six [96] study 
participants having type 2 diabetes mellitus 
fulfilled the inclusion criteria. Of the sampled 
population, the male-to-female ratio was near to 
one (46.7% males and 53.1% females). More than 
three fourth of the participants were older than 44 
years as shown in Table 1.  
As can be seen from Figure 1, more males 
were without NAFLD upon ultrasound liver 
examination than females. Nevertheless, the 
number of female patients with NAFLD was 
higher than male through all the fatty liver 
categories. The difference fails to attain 
statistically significant value despite increased 
number of female patients with NAFLD than 
males.  
The majority of the normal type 2 diabetic 
patients were with the disease for less than two 
years whereas a significant number of participants 
with NAFLD were diagnosed with the disease 
before two years. The duration of diabetes for all 
patients with severe fatty liver disease was more 
than seven years (Figure 2). The clinical 
characteristic that significantly affected non- 
alcoholic fatty liver disease was duration of 
diabetes mellitus (p=0.01). 
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                  Table 1: Socio-demographic characteristics of sampled Type 2 Diabetic patients attending diabetic clinic 

























Figure 1: Liver status and sex distribution of selected type 2 diabetic patients attending diabetic clinic of 
JUSH, 2015. DD: diabetic duration; MiLF: Mild Fatty Liver Disease; MLF: Moderate Fatty Liver Disease; 
SLF: Severe Fatty Liver Disease; p=0.101 
Variable  Type 2 Diabetic patients, n=96 Percentage (%) 
Sex Male 45 46.9 
Female 51 53.1 
Current Age < 25 years 1 1.1 
25 - 44 years 17 17.7 
45 - 64 years 63 65.6 
> 65 years 15 15.6  
Residence Rural 40 41.7 
Urban 47 48.9 
Others  9 9.4 
Religion Muslim  51 53.1 
Orthodox 10 10.4 
Protestant 35 36.5 
Occupation Employee 41 42.7 
Farmer 29 30.2 
Merchant 15 15.6 
Student 5 5.2 
House wife 6 6.3 
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Figure 2: Diabetic duration and liver status among type 2 diabetic patients attending diabetic clinic of 
JUSH, 2015. DD: Diabetic Duration; MiLF: Mild Fatty Liver Disease; MLF: Moderate Fatty Liver 
Disease; SLF: Severe Fatty Liver Disease; DD is significantly associated at p<0.05 
 
The anthropometric and clinical characteristics of 
the patients were presented in Table 2. Seventy of 
the study participants (73%) had non-alcoholic 
fatty liver disease (NAFLD) whereas the 
remaining patients’ liver ultrasound tests were 
negative. Of NAFLD documented patients 
35.4%, 31.3% and 6.3% exhibited mild, moderate 
and severe fatty liver diseases. The calculated 
BMI from height and weight revealed that half of 
the participants had BMI in normal range (18.0-
24.9). Twenty-eight patients had BMI in between 
25 to 29.9 kg/m2. The duration of diabetes 
mellitus for the majority of the patients was more 
than seven years (34.4%), whereas 27.1% and 
20.8% of them were with the disease for 5 to 7 
and 2 to 5 years, respectively. One hepatitis B 
and three hepatitis C patients among participants 
were excluded upon screening. All the study 
participants did not undergo any kind of fatty 
liver check-up before and .have any alcohol 
consumption history.  
 Table 2: Anthropometric and clinical 
characteristics of sampled type 2 diabetic patients 
attending diabetic clinic of Jimma University 
Specialized Hospital, Southwest Ethiopia. 
 
 
MiLF: Mild Fatty Liver Disease; MLF: Moderate Fatty Liver 





BMI  (kg/m2)                                                                   
23±0.41 
<18 14 14.6 
18.0-24.9 50 52.1 
25.0-29.9 28 29.1 
>=30 4 4.2 
Duration of DM 
(in Years) 
  
<2  17 17.7 
[2,5]  20 20.8 
(5,7]  26 27.1 
>7  33 34.4 
Liver Status Under Ultrasound 
Normal 26 27.0 
MiLF 34 35.4 
MLF 30 31.3 
         SLF 6 6.3 
 Fatty Liver Checking before this study 
Yes 0 0 




Yes 0 0 
No 96 100 
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The mean fasting blood glucose of the selected 
type 2 diabetic patients was 175±1.42 (p=0.67). 
Assessment of liver enzymes showed that normal 
type 2 diabetic patients had an averages of 
11.08±0.65 ALT while NAFL diseased patients 
had 15.90±1.07 among mild; 18.02±1.01 among 
moderate; 20.05±1.27 among severe. However, 
the measured values of AST and ALT were within 




Table 3: One-way ANOVA Analysis of NAFL disease with non significant biochemical and Lipid Profile 




































Regarding the lipid profile of our study 
participants, triacylglycerol was 157.77±10.44, 
180.03±5.10, 221.80±9.02 and 384.5±6.32 
among normal, NAFLD (mild), NAFLD 
(moderate) and NAFLD (severe), 
respectively. The total protein, high density 
lipoprotein and low density lipoprotein mean 
values were also measured (7.11±0.36, total 
protein; 33.3±2.04, high density lipoprotein; 
Variables  Liver Status  N Mean±SEM Sig. 
Fasting Blood Glucose (mg/dl)  Normal 26 163.21±1.25  
0.67 
 
Mild fatty liver 34 177.44±1.37 
Moderate fatty liver 30 186.56±1.18 
Sever fatty liver 6 172.80±1.87 
 
 









 0.44 Mild fatty liver 34 32.67±5.74 
Moderate fatty liver 30 33.48±2.05 
Sever fatty liver 6 23.35±1.54 
 
 











Mild fatty liver 34 7.24±0.19 
Moderate fatty liver 30 7.08±0.13 
Sever fatty liver 6 6.94±0.87 
 
 











Mild fatty liver 34 192.44±10.30 
Moderate fatty liver 30 175.39±9.12 
Sever fatty liver 6 189.99±26.56 
 
 











Mild fatty liver 34 36.72±1.80 
Moderate fatty liver 30 32.94±2.18 
Sever fatty liver 6 30.30±2.70 
 
 












Mild fatty liver 34 117.51±7.64 
Moderate fatty liver 30 101.80±6.37 
Sever fatty liver 6 106.01±7.34 
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109.7±7.41, low density lipoprotein (Table 3 and 
4).  
The statistical analysis of the study variables 
showed that there was a significant association 
between ALT, total bilirubin, direct bilirubin and 
triacylglycerol (TAG) concentration with non-
alcoholic fatty liver diseases. ALT and TAG are 
strongly associated with liver status (p=0.000) 
while direct bilirubin and total bilirubin have 
moderate association as compared to type 2 
diabetic patients without NAFLD. The mean value 
of ALT and direct bilirubin was significanlty 
different among type 2 diabetic patients with 
NAFD and without NAFLD at p ≤0.001 and p 
≤0.05, respectively. However, the moderate and 
mild fatty liver patients’ mean value of total 
bilirubin and the mild fatty liver values of TAG 
were not statisticantly higher than the normal type 
2 diabetic patients’ laboratory result (p≥0.05). Post 
hoc analysis revealed that the mean of ALT 
among severe fatty liver patients was significantly 
higher than the value obtained from mild fatty 
liver patients at p ≤0.05 while the difference 
between moderate and mild fatty liver patients 
failed to attain significant difference. The 
comparison of TAG indicated the result among 
severe fatty liver patients had strong statistical 
difference from the mean value of moderate and 
mild at p ≤0.0001. Unlike ALT, the mean value of 
TAG among moderate fatty liver patients 
(221.80±9.02) was higher than that of mild 
(180.03±5.10) (p=0.001) (Table 4).  
 
                  Table 4: One-way ANOVA and Post hoc analysis of variables significantly associated with the liver status 
among selected type 2 diabetic patients 
 
Variables          Liver Status        Mean±SEM p-value 
 
ALT (u/l) 
Normal  26 11.08±0.65 - 
Mild Fatty Liver 34 15.90±1.07 0.007 
Moderate Fatty Liver 30 18.02±1.01 0.000 
Severe Fatty Liver 6 21.72±1.37a 0.000 
 
 








Mild Fatty Liver 34 0.23±0.02 0.024 
Moderate Fatty Liver 30 0.23±0.02 0.023 
Severe Fatty Liver 6 0.19±0.04 0.012 
 
 








Mild Fatty Liver 34 0.40±0.04 0.118 
Moderate Fatty Liver 30 0.46±0.05 0.655 












Mild Fatty Liver 34 180.03±5.10  0.202 
Moderate Fatty Liver 30 221.80±9.02b 0.000 
Severe Fatty Liver 6 384.5±6.32cd 0.000 
p ≤0.05 was considered significant as compared to Normal type 2 diabetic patients 
aversus mild significant at p=0.04; b versus mild significant at p=0.001;   
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Non-alcoholic fatty liver disease is the most 
serious liver disorder and cause of cirrhosis among 
type two diabetic patients (7, 27, 28). Setting the 
objective of evaluating the occurrence of NAFLD 
and associated factors in type 2-Diabetic patients 
attending the Diabetic Center of Jimma University 
Specialized Hospital, Jimma, we evaluated 96 type 
2 daibetic patients who fulfilled the inclusion 
criteria. Seventy-three percent of the study 
participants had NAFLD along with type 2 
diabetic mellitus. The value was higher than the 
findings of studies done by Portillo-Sanchez et al 
(2015) (28), Adams et al (2010) (29), Merat et al 
(2009) (30) and a study done in Nigeria (31,32) 
where the respective prevalence were 49.5%, 
34.4%, 55.8% and 16.7%. The present finding is 
almost closer to research done in type 2 diabetic 
patients attending diabetic clinic of a tertiary care 
hospital in Mangalore (75% prevalence) (18). This 
could be due to lack of  liver checking habits as 
evidenced by the study participants’ report in 
Table 2. The other reason might be due to low 
attention given by health sector on fatty liver 
disease. The report of NAFLD among different 
sexes is not conclusive. Some reports confirm as 
high prevalence in women while recent studies 
came up with even distribution (33). The gender 
distribution of the present study showed that more 
females were affected by fatty liver diseases than 
males (Figure 1).  However, the difference was not 
significant at p≤0.05. 
Obesity was reported as the risk factor for 
NAFLD. In many research findings, a fatty liver 
disease among type 2 diabetic patients was 
significantly associated with BMI (16,18,28). In 
our findings, however, 50% of the participants had 
BMI in normal range (18.0-24.9) and only four 
patients were obese (BMI>30kg/m2). Moreover, 
BMI has no significant role in the disease 
progression (p>0.05). 
Liver failure causes fats to deposit around 
the liver tissue resulting in fatty liver disease 
which may increase or decrease liver 
enzymes. One of the major evidences to 
proove the presence of NAFLD is Liver 
Function Tests (LFTs). It is expected that 
patients with NAFLD have higher liver 
function test abnormalities than individuals 
who do not have NAFLD in diabetic patients 
(34). It is scientifically proved that ALT is 
more predictive of liver fat accumulation 
among the liver enzymes and correlate with 
liver fat independent of obesity (35). The 
results of this study showed that ALT (p 
≤0.001), total bilirubin (p ≤0.05) and direct 
bilirubin (p ≤0.05) are significantly associated 
with fatty liver diseases. Although the value 
of ALT is within normal range, its value is 
higher among NAFLD type 2 diabetic patients 
than normal type 2 diabetic patients. Research 
outputs in many other study areas showed that  
serum ALT levels are normal in patients with 
NAFLD. Hence, elevated ALT does not 
necessarily mean high hepatic damage (16). 
The AST value of NAFLD type 2 DM 
patients was not significantly different from 
that of normal type 2 patients (Table 3). On 
the other hand, the ratio of AST to ALT is 
greater than one in all the respective groups. 
The AST/ALT ratios were 2.1, 1.9 and 1.2 
among mild NAFLD, moderate NAFLD and 
severe NAFLD type 2 diabetic patients, 
respectively. Patients with NAFLD usually 
have a ratio of AST to ALT of <1(36). 
However, laboratory measures such as an 
AST to ALT ratio of >1 is predictors for hepatic 
fibrosis (35). Bilirubin has antioxidative and 
cytoprotectant effects (37). Report indicated 
inverse association of bilirubin with nonalcoholic 
fatty liver disease (38). The direct and total 
bilirubin level of the current study participants 
was higher among normal type 2 diabetic patients 
than mild and moderate NAFLD type 2 diabetic 
patients. Especially, type 2 diabetic patients with 
severe fatty liver have significantly lower bilirubin 
value than normal type 2 diabetic patients. Severe 
NAFLD patients’ total bilirubin was less than 
normal patients by half while the record of severe 
fatty liver patients’ direct bilirun was less by 
slightly higher than 40% (Tables 3 and 4).  
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 Triacylglycerol (TAG) is one of the  main 
factors affecting NAFLD in the present study. The 
mean value of TAG among type 2 diabetic 
patients with severe fatty liver was two times the 
laboratory mean results of normal and mild fatty 
liver patients. NAFLD is highly bonded with TAG 
accumulation in the hepatocytes. This store may 
arise from different sources including the intestine 
(through absorption), and the liver (synthesis). The 
high level of glucose or insulin will activate some 
transcription factors resulting in increased hepatic 
de novo lipogenesis. Finally, excessive lipolysis 
will form steatosis (4,6,12,39). Thus, the high 
level of TAG may be due to hyperglycemia and 
hyperinsulinemia as evidenced by the poor 
glycemic control (mean of FPG 175±1.42) (Table 
3). 
In conclusion the prevalence of NAFLD at 
the study site was 73%. ALT, TAG, direct and 
total bilirubin were the major significant 
determinants of NAFLD occurrence among type 2 
diabetic patients by either affecting the disease 
progression in positive or negative linear 
proportion.  Type 2 diabetic patients with NAFLD 
have significantly longer diabetic duration than 
normal type 2 diabetic patients.  Even though AST 
is not significantly associated with NAFLD; the 
AST/ALT ratio is greater than one.  
Non-alcoholic fatty liver diseases are the 
major risk factors for developing cardiovascular 
diseases (16), stroke, peripheral vascular disease 
(11), chronic kidney disease (40), cirrhosis and 
liver cancer (6) among type 2 diabetic patients. 
Therefore, the authors recommend further research 
across Ethiopia to know the pathogenesis and 
identify effective treatment options inclusive of 
NAFLD. 
While there is a real need to understand the true 
impact of NAFLD in developing countries and 
especially among type 2 DM patients, the size of 
the study population may not add much 
information to our current knowledge about the 
epidemiology of NAFLD in Ethiopia. Beside, the 
use of ultrasound and serum enzymes as the sole 
marker of NAFLD is another limitation as both 
modalities are not the most sensitive, specific and 
predictive method for detecting (quantifying) liver 
fat despite being cheap and accessible in 
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